Ossiam Has $5.77 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Ossiam decreased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 12.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,628 shares of the life sciences company’s stock after selling 1,582 shares during the period. Ossiam’s holdings in Illumina were worth $5,765,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in shares of Illumina by 5.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,539,352 shares of the life sciences company’s stock worth $1,198,406,000 after acquiring an additional 128,312 shares in the last quarter. Polen Capital Management LLC boosted its position in shares of Illumina by 4.4% during the 2nd quarter. Polen Capital Management LLC now owns 2,480,776 shares of the life sciences company’s stock worth $1,173,928,000 after acquiring an additional 103,747 shares in the last quarter. Ownership Capital B.V. boosted its position in shares of Illumina by 1.9% during the 2nd quarter. Ownership Capital B.V. now owns 1,023,891 shares of the life sciences company’s stock worth $484,515,000 after acquiring an additional 18,946 shares in the last quarter. Legal & General Group Plc boosted its position in shares of Illumina by 3.3% during the 2nd quarter. Legal & General Group Plc now owns 1,022,944 shares of the life sciences company’s stock worth $484,067,000 after acquiring an additional 32,705 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its position in shares of Illumina by 3.6% during the 1st quarter. Canada Pension Plan Investment Board now owns 731,784 shares of the life sciences company’s stock worth $281,049,000 after acquiring an additional 25,475 shares in the last quarter. Institutional investors and hedge funds own 88.56% of the company’s stock.

In other Illumina news, SVP Charles Dadswell sold 314 shares of the business’s stock in a transaction that occurred on Thursday, July 22nd. The shares were sold at an average price of $482.23, for a total value of $151,420.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Susan H. Tousi sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 4th. The stock was sold at an average price of $500.00, for a total transaction of $500,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 2,642 shares of company stock worth $1,268,895. Insiders own 0.23% of the company’s stock.

A number of analysts have weighed in on ILMN shares. Barclays raised their target price on shares of Illumina from $355.00 to $365.00 and gave the company an “underweight” rating in a research report on Friday, August 6th. SVB Leerink lowered shares of Illumina from an “outperform” rating to a “market perform” rating and set a $425.00 target price on the stock. in a research report on Thursday, August 19th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $504.00 target price on the stock in a research report on Wednesday, June 30th. Canaccord Genuity raised their target price on shares of Illumina from $515.00 to $555.00 and gave the company a “buy” rating in a research report on Monday, August 9th. Finally, Robert W. Baird restated a “hold” rating on shares of Illumina in a research report on Sunday, August 22nd. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $432.83.

Illumina stock traded up $4.88 during midday trading on Thursday, hitting $410.02. 7,987 shares of the stock were exchanged, compared to its average volume of 913,720. Illumina, Inc. has a 52-week low of $288.01 and a 52-week high of $555.77. The stock has a market capitalization of $60.15 billion, a price-to-earnings ratio of 77.61, a price-to-earnings-growth ratio of 2.24 and a beta of 0.91. The business’s 50-day moving average price is $454.67 and its 200-day moving average price is $439.18. The company has a quick ratio of 5.64, a current ratio of 6.08 and a debt-to-equity ratio of 0.32.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, August 5th. The life sciences company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.36 by $0.51. The business had revenue of $1.13 billion for the quarter, compared to analyst estimates of $1.01 billion. Illumina had a net margin of 19.36% and a return on equity of 18.12%. During the same quarter in the previous year, the firm posted $0.62 earnings per share. On average, sell-side analysts predict that Illumina, Inc. will post 6.48 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.

Further Reading: Trading Strategy

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.